Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting

The wide use of ruxolitinib, approved for treating primary and secondary myelofibrosis (MF), has revolutionized the landscape of these diseases. This molecule can reduce spleen volume and constitutional symptoms, guaranteeing patients a better quality of life and survival or even a valid bridge to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Duminuco, Andrea, Nardo, Antonella, Garibaldi, Bruno, Vetro, Calogero, Longo, Anna, Giallongo, Cesarina, Di Raimondo, Francesco, Palumbo, Giuseppe A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783796/
https://www.ncbi.nlm.nih.gov/pubmed/36556033
http://dx.doi.org/10.3390/jcm11247418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783796/
https://www.ncbi.nlm.nih.gov/pubmed/36556033
http://dx.doi.org/10.3390/jcm11247418

Ejemplares similares